Skip to content
Screener

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.32B+153%
Eli Lilly logo
Eli LillyLLY
$7.1B+25.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$5.53B-0.1%
Amgen logo
AmgenAMGN
$2.38B+65.9%
AbbVie logo
AbbVieABBV
$3.61B+285%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
-$69.71M-74.5%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Interest income4,6064,092
Other income (expense), net8(5)
Total other income, net4,6144,087
Net loss$(31,820)$(20,999)
Net loss per share attributable to common stockholders, basic and diluted$(0.48)$(0.40)
Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted$(39.81)$(32.95)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted55,172,41041,679,560
Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted137,138137,138

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s net income?
Oruka Therapeutics, Inc. (ORKA) reported net income of -$31.82M in Q1 2026.
How has Oruka Therapeutics, Inc.'s net income changed year-over-year?
Oruka Therapeutics, Inc.'s net income decreased by 51.5% year-over-year, from -$21M to -$31.82M.
What is the long-term trend for Oruka Therapeutics, Inc.'s net income?
Over 4 years (2021 to 2025), Oruka Therapeutics, Inc.'s net income has grown at a 52.8% compound annual growth rate (CAGR), from -$19.32M to -$105.43M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about Oruka Therapeutics, Inc.'s net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude